Established in 2008, the Beaulieu-Saucier Pharmacogenomics Centre is an academic organization dedicated to the advance of knowledge and promoting discoveries in precision medicine by leading high quality pharmacogenomics research in partnership with industry, governmental and academic organizations.
The Montreal Heart Institute Foundation raises and administers funds to support research, care, teaching, prevention, rehabilitation, and the assessment of new technologies at the Montreal Heart Institute.
Ecogène-21, a not-for-profit (NPO) clinical research organization dedicated to access innovation for unmet medical needs, coordinated from the Saguenay–Lac-Saint-Jean region. ECOGENE-21 has a solid experience and world-renowned expertise in the design, conduct and management of clinical trials, as well as the valorization of innovations designed to promote access to precision medicine with novel, safe, efficacious and affordable treatments.
Located within the McGill Genome Centre, the Centre of Genomics and Policy (CGP) works at the crossroads of law, medicine, and public policy. Applying a multidisciplinary perspective and collaborating with national and international partners, the CGP analyzes the socio-ethical and legal norms influencing the promotion, prevention and protection of human health.
The Quebec Research Group in Chronic Myeloid Leukemia and Myeloproliferative Neoplasia is a non-profit organization (NPO) created in 2011 with the objective of improving the management of certain hematological cancers by facilitating the linking of experts in the field (hematologists, pharmacists, nurses, scientists, etc.) to patients registered in pan-Quebec hematological cancer registries.
Hospitals and CIUSSS
Information Technologies In Health And Artificial Intelligence (AI)
Biopharmaceutical, Biotechnology And Investment Companies
InvHealth Capital Inc. (InvHealth) invests in business opportunities exclusively in the field of healthcare and with a favourable socio-economic balance. With constant rising healthcare costs, good science and clinical data alone are not enough: A successful and financially rewarding medical solution also has to be practical and affordable for the patients / payers.